glp-1 autoimmune disease Frontiers Microdosing GLP-1 for autoimmune conditions:

However, direct comparisons require caution because: Trial lengths differed Dosing protocols differed Patient populations differed Long-term orforglipron data is still developing A 5% to 10% reduction in body weight can still produce clinically meaningful improvements in blood pressure, insulin sensitivity, mobility, and metabolic health

At the same time, we are facing an exciting multifaceted future, with several novel developments on the horizon with the potential to change the clinic setting, including the development of oral GLP-1 receptor agonists and the emerging formulations of GIP receptor agonists and dual and triple receptor agonists, which have shown clear therapeutic potential

Harnessing artificial intelligence to predict ovarian stimulation outcomes in in vitro fertilization: scoping review

If your thyroid function tests show unexpected changes after starting semaglutide, your doctor may adjust your levothyroxine dose

We have also demonstrated the thermal stability of semaglutide at extreme temperature (80 C for 1h) for the use in this PSR-MNs system

Injectable versus oral: the evidence gap The choice between injectable and oral formulations is one of the most important decisions in GLP-1 therapy